Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis - Takeaways - MDSpire

Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis

  • By

  • Ahmed B Bayoumy

  • Lindsay M Clarke

  • Parakkal Deepak

  • Aakash Desai

  • Priya Sehgal

  • uri Gorelik

  • Haggai Bar-Yoseph

  • Marie Villumsen

  • Chris J J Mulder

  • Dirk J Stenvers

  • Maarten E Tushuizen

  • Nanne K H de Boer

  • October 10, 2025

  • 0 min

Share

  • 1

    GLP1-RAs may improve clinical outcomes in patients with inflammatory bowel disease (IBD), particularly those with obesity.

  • 2

    A systematic review included 11 studies with 16,242 IBD patients treated with GLP1-RAs, focusing on weight loss and IBD-related outcomes.

  • 3

    Significant weight loss was observed with GLP1-RAs: semaglutide (−9.6 kg), liraglutide (−9.4 kg), and tirzepatide (−11.8 kg) after 3 months.

  • 4

    GLP1-RAs were associated with a lower risk of surgery and hospitalizations in IBD patients, especially those with obesity.

  • 5

    Further prospective trials are needed to confirm the findings regarding the efficacy and safety of GLP1-RAs in IBD.

Original Source(s)

Related Content